# Effective Spesolimab Treatment for Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report

## TL;DR

This case report describes a successful treatment of generalized pustular psoriasis with spesolimab, a drug targeting the IL-36 receptor.

## Contribution

The report highlights spesolimab's efficacy in a complex GPP case with AGEP-like features, emphasizing accurate diagnosis.

## Key findings

- Spesolimab rapidly relieved symptoms in a GPP patient with AGEP-like features.
- Accurate diagnosis is crucial for effective treatment of GPP.
- Real-world evidence supports spesolimab's role in managing severe GPP flares.

## Abstract

Generalized pustular psoriasis (GPP) is a rare and severe variant of psoriasis, often posing diagnostic challenges due to its clinical overlap with acute generalized exanthematous pustulosis (AGEP), a severe drug-induced hypersensitivity reaction. Spesolimab, a monoclonal antibody targeting the interleukin 36 (IL-36) receptor, provides rapid symptom relief for GPP flares, but real-world data remain limited. We report a case of GPP complicated by overlapping features with AGEP, highlighting the importance of precise diagnosis and the efficacy of spesolimab.